DODianne L. O'Connell

Dianne L. O'Connell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dianne L. O'Connell has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A New Integrative Modeling Approach for Generating Counterfactual Projections of Colorectal Cancer Incidence Rates in the Absence of Organized Screening in Australia

    by Qingwei Luo, Jie-Bin Lew, Joachim Worthington, Clare Kahn, Han Ge, Emily He, Michael Caruana, Michael David, Dianne L O’COnnell, Karen Canfell, et al.

    Background: The Australian National Bowel Cancer Screening Program (NBCSP), which provides 2-yearly screening to people aged 50 to 74 y, had a phased rollout from 2006 and was fully implemented in 2020. To measure the effectiveness of the NBCSP accounting for age-specific trends, we aimed to develop a novel integrative method to project colorectal cancer (CRC) incidence rates from 2006 to 2045 in the absence of the NBCSP (referred to as “no-NBCSP projections”) while addressing the challenge of complex age-specific trends in CRC incidence. Methods: We constructed a new dataset by replacing the observed data for NBCSP-eligible individuals aged 50 to 74 y with intermediate projections based on pre-NBCSP data from 1982 to 2005. We compared the no-NBCSP CRC incidence projected using a standard age-period-cohort (APC) model, age-stratified APC models, and the integrative modeling approach. Results: The integrative modeling approach captured complex age-specific trends better than the standard and age-stratified APC models did. Without the NBCSP, the overall CRC incidence rates would be expected to decline from 2005 to 2025, followed by increases from 2026 to 2045. The incidence rates for those aged <50 y would be projected to continue increasing to 2045, and an increase in incidence rates for older age groups would be projected to occur from 2020 for ages 50 to 54 y, from 2030 for ages 65 to 74 y, and from 2035 for ages 75 y and older. Conclusions: These no-NBCSP projections provide a counterfactual benchmark against which to measure the impact of the NBCSP on CRC incidence in Australia, and they have been used as new calibration targets for a simulation model of CRC and screening in Australia. The methods developed here could be used to generate comparators to assess the impact of other public health interventions. Highlights: We constructed counterfactual projections of colorectal cancer (CRC) incidence rates in the absence of the National Bowel Cancer Screening Program (no-NBCSP projections). To do this, we developed a new integrative modeling approach to capture complex age-specific colorectal cancer incidence trends. These no-NBCSP projections provide a counterfactual benchmark against which to measure the impact of the NBCSP on CRC incidence in Australia. These projections stress the need for ongoing assessment of the starting age for the NBCSP, to tackle the increasing incidence for people younger than 50 y.


  • Open Access

    Recalibrating an Established Microsimulation Model to Capture Trends and Projections of Colorectal Cancer Incidence and Mortality

    by Jie-Bin Lew, Qingwei Luo, Joachim Worthington, Han Ge, Emily He, Julia Steinberg, Michael Caruana, Dianne L. O’cOnnell, Eleonora Feletto, Karen Canfell

    Background: Changing colorectal cancer (CRC) incidence rates, including recent increases for people younger than 50 y, need to be considered in planning for future cancer control and screening initiatives. Reliable estimates of the impact of changing CRC trends on the National Bowel Cancer Screening Program (NBCSP) are essential for programmatic planning in Australia. An existing microsimulation model of CRC, Policy1-Bowel , was updated to reproduce Australian CRC trends data and provide updated projections of CRC- and screening-related outcomes to inform clinical practice guidelines for the prevention of CRC. Methods: Policy1-Bowel was recalibrated to reproduce statistical age-period-cohort model trends and projections of CRC incidence for 1995–2045 in the absence of the NBCSP as well as published data on CRC incidence trends, stage distribution, and survival in 1995–2020 in Australia. The recalibrated Policy1-Bowel predictions were validated by comparison with published Australian CRC mortality trends for 1995–2015 and statistical projections to 2040. Metamodels were developed to aid the calibration process and significantly reduce the computational burden. Results: Policy1-Bowel was recalibrated, and best-fit parameter sets were identified for lesion incidence, CRC stage progression rates, detection rates, and survival rates by age, sex, bowel location, cancer stage, and birth year. The recalibrated model was validated and successfully reproduced observed CRC mortality rates for 1995–2015 and statistical projections for 2016–2030. Conclusion: The recalibrated Policy1-Bowel model captures significant additional detail on the future incidence and mortality burden of CRC in Australia. This is particularly relevant as younger cohorts with higher CRC incidence rates approach screening ages to inform decision making for these groups. The metamodeling approach allows fast recalibration and makes regular updates to incorporate new evidence feasible. Highlights: In Australia, colorectal cancer incidence rates are increasing for people younger than 50 y but decreasing for people older than 50 y, and colorectal cancer survival is improving as new treatment technologies emerge. To evaluate the future health and economic impact of screening and inform policy, modeling must include detailed trends and projections of colorectal cancer incidence, mortality, and diagnosis stage. We used novel techniques including integrative age-period cohort projections and metamodel calibration to update Policy1-Bowel , a detailed microsimulation of colorectal cancer and screening in Australia.


  • Open Access

    Supplementary Table S1 from Decline in the Incidence of Distant Recurrence of Breast Cancer: A Population-Based Health Record Linkage Study, Australia 2001–2016

    by Sarah J. Lord, Benjamin Daniels, Dianne L. O'Connell, Belinda E. Kiely, Jane Beith, Andrea L. Smith, Sallie-Anne Pearson, Kim-Lin Chiew, Max K. Bulsara, Nehmat Houssami

    Supplementary Table S1: Data sources and criteria for classifying distant recurrence from administrative health records.

  • Open Access

    Supplementary Table S3 from Decline in the Incidence of Distant Recurrence of Breast Cancer: A Population-Based Health Record Linkage Study, Australia 2001–2016

    by Sarah J. Lord, Benjamin Daniels, Dianne L. O'Connell, Belinda E. Kiely, Jane Beith, Andrea L. Smith, Sallie-Anne Pearson, Kim-Lin Chiew, Max K. Bulsara, Nehmat Houssami

    Supplementary Table S3: Cumulative incidence of distant recurrence (%) and absolute risk difference at 5 and 9 years after breast cancer diagnosis, 2001-2002 and 2006-2007 cohorts, by area-level socioeconomic status (more disadvantaged, less disadvantaged) and age group (<50, 50-69, ≥70 years).

  • Open Access

    Supplementary Figure S2 from Decline in the Incidence of Distant Recurrence of Breast Cancer: A Population-Based Health Record Linkage Study, Australia 2001–2016

    by Sarah J. Lord, Benjamin Daniels, Dianne L. O'Connell, Belinda E. Kiely, Jane Beith, Andrea L. Smith, Sallie-Anne Pearson, Kim-Lin Chiew, Max K. Bulsara, Nehmat Houssami

    Supplementary Figure S2: Study flowchart showing the number of women with a first diagnosis of primary invasive breast cancer in New South Wales in 2001-2002 and 2006-2007, number included in the study cohorts, and reasons for exclusions.

  • Open Access

    Supplementary Table S2 from Decline in the Incidence of Distant Recurrence of Breast Cancer: A Population-Based Health Record Linkage Study, Australia 2001–2016

    by Sarah J. Lord, Benjamin Daniels, Dianne L. O'Connell, Belinda E. Kiely, Jane Beith, Andrea L. Smith, Sallie-Anne Pearson, Kim-Lin Chiew, Max K. Bulsara, Nehmat Houssami

    Supplementary Table S2: Adjuvant therapy dispensed for breast cancer distant recurrence-free at 12 months after diagnosis, 2006–2007 cohort, by area-level socioeconomic status (more disadvantaged, less disadvantaged), and categorized by extent of disease at diagnosis (localized, regional) and age group (<50, 50-69, ≥70 years).

  • Open Access

    Supplementary Table S3 from Decline in the Incidence of Distant Recurrence of Breast Cancer: A Population-Based Health Record Linkage Study, Australia 2001–2016

    by Sarah J. Lord, Benjamin Daniels, Dianne L. O'Connell, Belinda E. Kiely, Jane Beith, Andrea L. Smith, Sallie-Anne Pearson, Kim-Lin Chiew, Max K. Bulsara, Nehmat Houssami

    Supplementary Table S3: Cumulative incidence of distant recurrence (%) and absolute risk difference at 5 and 9 years after breast cancer diagnosis, 2001-2002 and 2006-2007 cohorts, by area-level socioeconomic status (more disadvantaged, less disadvantaged) and age group (<50, 50-69, ≥70 years).

  • Open Access

    Supplementary Figure S1 from Decline in the Incidence of Distant Recurrence of Breast Cancer: A Population-Based Health Record Linkage Study, Australia 2001–2016

    by Sarah J. Lord, Benjamin Daniels, Dianne L. O'Connell, Belinda E. Kiely, Jane Beith, Andrea L. Smith, Sallie-Anne Pearson, Kim-Lin Chiew, Max K. Bulsara, Nehmat Houssami

    Supplementary Figure S1: Timeline of Pharmaceutical Benefits Scheme subsidization of adjuvant taxanes and targeted therapies for breast cancer in Australia, 1995-2016.

  • Open Access

    Data from Decline in the Incidence of Distant Recurrence of Breast Cancer: A Population-Based Health Record Linkage Study, Australia 2001–2016

    by Sarah J. Lord, Benjamin Daniels, Dianne L. O'Connell, Belinda E. Kiely, Jane Beith, Andrea L. Smith, Sallie-Anne Pearson, Kim-Lin Chiew, Max K. Bulsara, Nehmat Houssami

    Background:We investigated differences in cumulative incidence of first distant recurrence (DR) following non-metastatic breast cancer over a time period when new adjuvant therapies became available in Australia.Methods:We conducted a health record linkage study of females with localized (T1–3N0) or regional (T4 or N+) breast cancer in the New South Wales Cancer Registry in 2001 to 2002 and 2006 to 2007. We linked cancer registry records with administrative records from hospitals, dispensed medicines, radiotherapy services, and death registrations to estimate the 9-year cumulative incidence of DR and describe use of adjuvant treatment.Results:The study included 13,170 women (2001–2002 n = 6,338, 2006–2007 n = 6,832). The 9-year cumulative incidence of DR was 3.6% [95% confidence interval (CI), 2.3%–4.9%] lower for 2006–2007 diagnoses (15.0%) than 2001–2002 (18.6%). Differences in the annual hazard of DR between cohorts were largest in year two. DR incidence declined for localized and regional disease. Decline was largest for ages <40 years (absolute difference, 14.4%; 95% CI, 8.3%–20.6%), whereas their use of adjuvant chemotherapy (2001–2002 49%, 2006–2007 75%) and HER2-targeted therapy (2001–2002 0%, 2006–2007 16%) increased. DR did not decline for ages ≥70 years (absolute difference, 0.9%; 95% CI, −3.6%–1.8%) who had low use of adjuvant chemotherapy and HER2-targeted therapy.Conclusions:This whole-of-population study suggests that DR incidence declined over time. Decline was largest for younger ages, coinciding with changes to adjuvant breast cancer therapy.Impact:Study findings support the need for trials addressing questions relevant to older people and cancer registry surveillance of DR to inform cancer control programs.

  • Open Access

    Data from Decline in the Incidence of Distant Recurrence of Breast Cancer: A Population-Based Health Record Linkage Study, Australia 2001–2016

    by Sarah J. Lord, Benjamin Daniels, Dianne L. O'COnnell, Belinda E. Kiely, Jane Beith, Andrea L. Smith, Sallie-Anne Pearson, Kim-Lin Chiew, Max K. Bulsara, Nehmat Houssami

    Background:We investigated differences in cumulative incidence of first distant recurrence (DR) following non-metastatic breast cancer over a time period when new adjuvant therapies became available in Australia.Methods:We conducted a health record linkage study of females with localized (T1–3N0) or regional (T4 or N+) breast cancer in the New South Wales Cancer Registry in 2001 to 2002 and 2006 to 2007. We linked cancer registry records with administrative records from hospitals, dispensed medicines, radiotherapy services, and death registrations to estimate the 9-year cumulative incidence of DR and describe use of adjuvant treatment.Results:The study included 13,170 women (2001–2002 n = 6,338, 2006–2007 n = 6,832). The 9-year cumulative incidence of DR was 3.6% [95% confidence interval (CI), 2.3%–4.9%] lower for 2006–2007 diagnoses (15.0%) than 2001–2002 (18.6%). Differences in the annual hazard of DR between cohorts were largest in year two. DR incidence declined for localized and regional disease. Decline was largest for ages <40 years (absolute difference, 14.4%; 95% CI, 8.3%–20.6%), whereas their use of adjuvant chemotherapy (2001–2002 49%, 2006–2007 75%) and HER2-targeted therapy (2001–2002 0%, 2006–2007 16%) increased. DR did not decline for ages ≥70 years (absolute difference, 0.9%; 95% CI, −3.6%–1.8%) who had low use of adjuvant chemotherapy and HER2-targeted therapy.Conclusions:This whole-of-population study suggests that DR incidence declined over time. Decline was largest for younger ages, coinciding with changes to adjuvant breast cancer therapy.Impact:Study findings support the need for trials addressing questions relevant to older people and cancer registry surveillance of DR to inform cancer control programs.